BI 706321 + itraconazole

BI 706321 + itraconazole is a combination consisting of BI 706321, a potent and selective small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 2 (RIPK2), and itraconazole, an anti-fungal medicine acting as a strong CYP3A4 inhibitor. BI 706321 is under investigation primarily for Crohn’s disease, aiming to blunt NOD1/2-driven inflammatory responses in the gut, thereby reducing mucosal inflammation and promoting epithelial healing. The combination is used in clinical pharmacokinetic studies to assess potential drug-drug interactions, specifically how itraconazole, by inhibiting CYP3A4, alters the pharmacokinetics of BI 706321. BI 706321 is developed and sponsored by Boehringer Ingelheim[1][2][6]. Itraconazole is developed and manufactured by Janssen. The combination is not intended as a therapeutic treatment, but rather for evaluating metabolism and safety profiles of BI 706321 in the presence of a CYP3A4 inhibitor.

Other names

BI706321 + itraconazole